GPSI Targets India for New Drug Development

9 September 2009 (Last Updated September 9th, 2009 18:30)

Global Pharmaceutical Services Inc (GPSI), a leader in pharmaceutical and biotechnology research and development support, has announced a new partnership to outsource clinical studies to India. The company has extended its presence to the sub-continent through a new partnership with Abr

Global Pharmaceutical Services Inc (GPSI), a leader in pharmaceutical and biotechnology research and development support, has announced a new partnership to outsource clinical studies to India.

The company has extended its presence to the sub-continent through a new partnership with Abridge Clinical Research, a research and development company located in Mumbai, India.

This pact offers services including contract research organisation selection for a specific clinical programme, monitoring of clinical studies, auditing, quality assurance, design and conduct of Phase I–IV clinical studies.

The agreement also includes faster patient enrollment, in-country sponsor representatives, medical writing, data management, biostatistical services and regulatory support.

Abridge director Emran Khan said that India has become the hub of clinical research.

“In today’s recession, India has become the favourite place for outsourcing clinical studies,” Khan said.

GPSI is now marketing itself as the point of contact for US businesses that are interested in conducting clinical studies in India.